
Research Article

Detection of Antibiotic Resistance genes of Multidrug Resistance Enterobacter Cloacae and Enterobacter Aerogenes Isolated from the Patients of Dhaka Medical College Hospital

Azmeri Haque¹, Nafisa Jabin Mishu², H M Khaleduzzaman^{*3}, S M Shamsuzzaman⁴, Avizit Sarker⁵, MD Zabed Ahmed Mitu⁶, Rizwana Zaman⁷, Rubaiya Binte Kabir⁸, MD Asaduzzaman⁹

Abstract

Emergence of multidrug resistant strains of Enterobacter spp. has a potential threat because these strains were responsible for high morbidity and mortality in recent years due to nosocomial infection in health care settings. Due to shortage of new effective antibiotic, old drug like fosfomycin recently reintroduced in human medicine for the treatment of multi drug resistant (MDR) gram negative bacteria. Sample size was 360. We collected different samples like urine, wound swab, endotracheal aspirate and blood from microbiology lab of Dhaka medical college. Organisms were isolated and identified by culture, gram staining and biochemical tests. Further tests were done only on common Enterobacter species. Antibiotic susceptibility tests were performed by disc diffusion technique. Polymerase chain reaction (PCR) was used to identify different colistin resistance genes (mcr-1 and mcr-2), fosfomycin resistance genes (fosA, fosA3, fosA4) and carbapenem resistance genes (blaKPC, blaIMP, blaVIM and blaOXA-48 / blaOXA181). Sequencing of fosA4 gene was done. Present study observed the presence of fosfomycin resistance gene of multidrug resistant (MDR) Enterobacter spp. Among the 360 samples 66.11% yielded culture positive results and out of the culture positive samples 10.53% were Enterobacter spp. Among Enterobacter spp. 82.76% E. cloacae and 17.24% E. aerogenes were identified by biochemical tests. Among the 17.24% isolated E. aerogenes, 100% were resistant to amoxiclav and cefoxitin and ceftazidime, 80% were resistant to ciprofloxacin and amikacin, 60% were resistant to piperacillin-tazobactam, cefuroxime and ceftriaxone, 40% were resistant to aztreonam, cefepime and fosfomycin, 20% were resistant to imipenem and colistin but none were resistant to tigecycline. Among the fosfomycin resistant Enterobacter spp. 80% were positive for fosA gene, 50% were positive for fosA4 gene, 50% were positive for fosA5 gene. Sequencing of PCR product of fosA4 gene showed multiple point mutations. So, Antimicrobial susceptibility testing must be done before prescribing antibiotics due to the high rates of resistance of Enterobacter spp. to multiple antibiotics.

Keywords: Enterobacter cloacae, Enterobacter aerogenes, fosfomycin, antibiotic resistance, genes, MDR, Polymerase chain reaction; Agar dilution method

Introduction

The genus Enterobacter is associated with hospital acquired infection that has been ranked as the third most frequent isolate following Escherichia coli and Klebsiella species [1]. Enterobacter cloacae and Enterobacter

Affiliation:

¹MBBS, M phil (Microbiology), Lecturer, Department of microbiology, Dhaka Medical College, Bangladesh

²MBBS, M phil (Microbiology), Assistant professor, Microbiology, Army Medical College Bogura, Bangladesh

³MBBS, FCPS(Medicine), Classified medicine specialist CMH Bogura, Bangladesh

⁴MBBS, Mphil (Microbiology), PHD, Prof of microbiology, Department of microbiology Dhaka Medical College Dhaka, Bangladesh

⁵MBBS (DMC), MD (Microbiology), Medical Officer, Department of Microbiology Dhaka Medical College, Bangladesh

⁶Associate Professor, Department of Microbiology, Jahurul Islam medical College, Bangladesh

⁷Assistant Professor (c.c), Department of Microbiology, Dhaka Medical College, Bangladesh

⁸Lecturer, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh

⁹MBBS, M. Phil, Lecturer, Dhaka Medical College, Bangladesh

*Corresponding author:

H M Khaleduzzaman, MBBS, FCPS(Medicine), Classified medicine specialist CMH Bogura, Bangladesh

Citation: Azmeri Haque, Nafisa Jabin Mishu, H M Khaleduzzaman, S M Shamsuzzaman, Avizit Sarker, MD Zabed Ahmed Mitu, Rizwana Zaman, Rubaiya Binte Kabir, MD Asaduzzaman. Detection of Antibiotic Resistance genes of Multidrug Resistance Enterobacter Cloacae and Enterobacter Aerogenes Isolated from the Patients of Dhaka Medical College Hospital. Archives of Microbiology and Immunology. 7 (2023): 143-149.

Received: July 24, 2023

Accepted: August 01, 2023

Published: August 10, 2023

aerogenes are the most commonly isolated species among the *Enterobacter* species [2].

National Nosocomial Infection Surveillance System (NNIS) study found that *Enterobacter* accounts for 5 to 11% of all nosocomially transmitted blood, wound, respiratory tract and urinary tract infections. *Enterobacter* spp. caused 11.2% of pneumonia cases in all types of ICUs, ranking third after *Staphylococcus aureus* (18.1%) and *P. aeruginosa* (17%). The corresponding rates among patients in pediatric ICUs were 9.8% for pneumonia, 6.8% for bloodstream infections, and 9.5% for UTIs [3]. *Enterobacter* spp. appears well adapted for survival and threats to cause immense mortality & morbidity by the proliferation of highly drug resistant strains both in the community and hospital environment. These organisms seem to have innate resistance to older anti-microbial agents and have the propensity to rapidly develop resistance to newer anti-microbial agents [4]. Treatment of infections with *Enterobacter* spp. is difficult because of resistance to third generation cephalosporins, penicillin and quinolones is an increasing problem [5].

Enterobacter cloacae can produce chromosome mediated AmpC β -lactamase and are resistant to ampicillin, amoxicillin/clavulanic, cephamycin and first and second generation cephalosporin [6]. Due to the clinical significance of their AmpC- β -lactamase production, these pathogens are a part of the "SPICE" (*Serratia*, *Pseudomonas*, indole-positive *Proteus*, *Citrobacter* and *Enterobacter*) of bacteria [7] which is usually associated with complicated UTI (associated with catheters, functional or anatomical abnormalities of genitourinary tract). The carbapenem non-susceptible phenotypes are attributed to production of carbapenemases or more likely, production of extended-spectrum β lactamase (ESBL) plus AmpC β -lactamase with dysfunctional entry routes (i.e., porin change) of carbapenems, integrons and insertion sequence common region 1 (ISCR1) carrying various resistance genes, and/or efflux pumps etc [8]. Also, the mechanism of combinations of either ESBL or AmpC and mutation of porins may hold a certain proportion [9]. Therefore, it is no surprise that the carbapenem resistant *Enterobacter* spp. is a part of the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.). The purpose of this study was to identify the patterns of antibiotic resistance in *Enterobacter* species isolated from various clinical cases. Additionally, common *Enterobacter* species that cause a variety of diseases were found. In addition to reducing treatment failure in hospitalized patients, this would offer crucial information about the empiric management of *Enterobacter* infections.

Materials and Methods

Total of 29 *Enterobacter* isolates were gathered from various samples of urine, wound swab, endotracheal

aspirate and blood during the course of a year (June 2019 to July 2020) in the microbiology department at Dhaka Medical College. The *Enterobacter* isolates were tested for antibiotic susceptibility using the Kirby Bauer disc diffusion method with Mueller Hinton agar and commercially available antibiotic discs (Oxoid Ltd, UK). Amoxycillin / clavulanic acid (20/10 μ g), Cefepime (30 μ g), Ceftazidime (30 μ g), Cefuroxime sodium (30 μ g), Cefoxitin (30 μ g), Amikacin (30 μ g), Ceftriaxone (30 μ g), Ciprofloxacin (30 μ g), Piperacillin/Tazobactam (110/10 μ g), Imipenem (10 μ g), Tigecycline (15 μ g), Gentamycin (30 μ g) were used. Colistin and fosfomycin (Beximco Pharma Limited) susceptibility was tested by was determined by agar dilution method of MIC. The disc content and the zone of inhibition were used as recommended by the Clinical Laboratory Standards Institute (CLSI, 2020). Criteria of the United States Food and Drug Administration (2010) were used for the interpretation of zone of inhibition of Tigecyclin. Antibiotic discs were obtained from commercial source (Oxoid Ltd.UK). For inoculum preparation & inference of MIC 0.5 McFarland turbidity was used as standard (contains 1 \times 10⁸ cfu/ml) [10] 10 times dilution of the test inoculum was done to achieve 1 \times 10⁷ cfu/ml. All the inoculated plates were incubated aerobically at 37°C overnight and the lowest concentration of antibiotic impregnated Mueller-Hinton agar which showing no visible growth on agar media was considered as MIC of the drug of that strain of bacteria *E. coli* ATCC 25922 was used for quality control.

Two species of *Enterobacter*, *E. cloacae* and *E. aerogenes* were identified using several biochemical tests including sugar fermentation test for Adonitol, D-sorbitol, L-rhamnose and Esculin and by two decarboxylation reactions- Arginine dihydrolase test and Lysine decarboxylase test. Species other than these two were categorized as others. Polymerase chain reaction (PCR) was done for the detection of MDR genes in *Enterobacter* spp. Bacterial pellet formation was done by a loop full of bacterial colonies from Mueller Hinton agar (MHA) media was inoculated into a microcentrifuge tube having sterile TSB and incubated overnight at 37°C. Centrifugation of the incubated tube was done at 4000g for 10 minutes. Supernatant part was discarded and tubes containing bacterial pellets were kept at -20°C for the purpose of DNA extraction. To extract the DNA three hundred microlitre of sterile distilled water was added to microcentrifuge tubes having pellets and vortexed until mixed well. Then the mixture was heated at 100° C for 10 minutes in a heat block. After heating, tubes were immediately placed on ice for 5 minutes and centrifuged at 14000 g for 6 minutes at 4°C. Finally, the supernatant was taken into another microcentrifuge tube. This extracted DNA was preserved at 4°C for 7-10 days and -20°C for a long time. Mixing of mastermix with primer and DNA template PCR was performed in a final reaction volume 25 μ l in a PCR tube, containing 12.5 μ l of master mix (mixture of dNTP, taq polymerase, MgCl₂ and PCR buffer), 2 μ l forward

primer, 2 µl reverse primer (Promega Corporation, USA), 2 µl of extracted DNA and 6.5 µl of nuclease free water. After a brief vortex, the tubes were centrifuged. Amplification in thermal cycler (Gene Atlas, Master cycler gradient, Japan, Model482) PCR assays was performed in a DNA thermal cycler. After amplification products were processed for gel documentation or kept at -20°C till tested (Gene Atlas, Master cycler gradient, Japan, Model 482).

Agarose gel electrophoresis and visualization PCR products were detected by electrophoresis on 1.5% agarose gel. Gel was prepared with 1 X TBE buffer (Tris EDTA). For 1.5% agarose gel preparation, 0.18 gram agarose powder (LE, analytic grade, Promega, Madison, USA) was mixed with a 1.25 ml TBE buffer. A comb was placed in a gel tray, the gel was poured. After solidification, 1 µl of loading dye and 5 µl of amplicon was mixed on parafilm and was loaded in agarose well. Similarly, 2 µl of 100bp DNA ladder was mixed with 1µl loading dye and was loaded. Gel electrophoresis was done in 230 voltages for 30 minutes. After electrophoresis, the gel was stained with ethidium bromide (20µl ethidium bromide in 200 ml distilled water). The gel was observed under UV transilluminator (Gel Doc, Major Science, Taiwan) for DNA bands. The DNA bands were identified according to their molecular size by comparing with the molecular weight marker (100bp DNA ladder) loaded in a separated lane. For sequencing of bacterial DNA, purification of amplified PCR products was done by using DNA purification kits (FAVOGEN, Biotech Corp). Purified PCR products of *Proteus mirabilis* were sent to 1st Base Laboratories, Malaysia for sequencing by capillary method (ABI PRISM 3500). BLAST analysis was performed to search for homologous sequences into the Gene Bank at www.ncbi.nlm.nih.gov. Primers used in this study (27, 28, 29, 30, 31):

Result

Among the 360 samples 66.11% yielded culture positive results and out of the culture positive samples 10.53% were *Enterobacter* spp. Figure-1 showed the distribution of isolated *Enterobacter* into different species. Out of 29 *Enterobacter* isolates, 24(82.76%) were *E. cloacae* and 5(17.24%) were *E. aerogenes*.




Figure1: Distribution *Enterobacter* spp among the sample

Fig-2 showed among 128 urine sample, 8 (6.25%) were *E. cloacae* and 2 (1.56%) were *E. aerogenes*, among wound swab 06.96% were *E. cloacae* and 1.74% was *E. aerogenes*. among blood 1.75% were *E. cloacae* but none was *E. aerogenes*. and among 60 endotracheal aspirates, 7(11.66%) were *E. cloacae* and one (1.66%) was *E. aerogenes*.




Figure 2: Distribution of *E. cloacae* and *E. aerogenes* isolated from different samples.

Table 1 shows among the 5 isolated *E. aerogenes*, 100% were resistant to amoxiclav and cefoxitin and ceftazidime, 80% were resistant to ciprofloxacin and amikacin, 60% were resistant to piperacillin-tazobactam, cefuroxime and ceftriaxone, 40% were resistant to aztreonam, cefepime and fosfomycin, 20% were resistant to imipenem and colistin but none were resistant to tiger cycline.

Table 1: Antibiotic resistance pattern of isolated *E. cloacae* and *E. aerogenes* (N=29)

Antimicrobial drugs	<i>E. cloacae</i>	<i>E. aerogenes</i>	Total N=29
	N=24 n (%)	N=5 n (%)	n (%)
Amoxiclav	24 (100.00)	5 (100.00)	29 (100.00)
Cefoxitin	24 (100.00)	5 (100.00)	29 (100.00)
Ciprofloxacin	21 (87.50)	4 (80.00)	25 (86.21)
Cefuroxime	24 (100.00)	3 (60.00)	27 (93.10)
Ceftriaxone	22 (91.67)	3 (60.00)	25 (86.21)
Ceftazidime	17 (70.83)	5 (100.00)	22 (75.86)
Aztreonam	17 (70.83)	2 (40.00)	19 (65.52)
Amikacin	12(50.00)	4 (80.00)	16 (55.17)
Imipenem	12 (50.00)	1 (20.00)	13 (44.83)
Piperacilin-tazobactam	11 (45.83)	3(60.00)	14 (48.27)
*Fosfomycin	8 (33.33)	2 (40.00)	10 (34.48)
Cefepime	7 (29.17)	2 (40.00)	9 (31.03)
*Colistin	7(29.17)	1 (20.00)	8 (27.59)
Tigecycline	4 (16.66)	0 (0.00)	4 (13.79)

N= Total number of isolated bacteria n =Total number of resistant bacteria

*Colistin and Fosfomycin resistance was determined by MIC by agar dilution method.

Table 2 shows distribution of multidrug resistant *Enterobacter* spp. isolated from different samples. Out of 29 isolated *E. cloacae* and *E. aerogenes*, 17 multidrug resistant strains were detected. Of which, 5 (50%) were detected from urine, 6 (60%) from wound swab, 5 (62.50%) from endotracheal aspirates, one (100%) from blood sample.

Table 2: Distribution of multidrug resistant (MDR) *E. cloacae* and *E. aerogenes* isolated from different samples

Sample	Total isolates	MDR isolates
	N=29	n (%)
Urine	10	5 (50.00)
Wound swab	10	6 (60.00)
ETA	8	5 (62.5)
Blood	1	1 (100.00)
Total	29	17 (58.62)

ETA= Endotracheal aspirate

N= Total number of isolated *E. cloacae* and *E. aerogenes*

n = Total number of MDR isolates.

Table 3: shows antimicrobial resistance pattern of the isolated MDR *Enterobacter* spp. Among the 17 isolated *E. cloacae* and *E. aerogenes*, all were resistant to amoxiclav, amikacin and cefoxitin, 88.23 % were resistant to ciprofloxacin, 94.12 % were resistant to ceftriaxone, cefuroxime and ceftazidime, 70.59% were resistant to piperacillin-tazobactam, 76.47% were resistant to imipenem, 47.06 % were resistant to fosfomycin, 41.17% were resistant to colistin and 23.53% were resistant to tigecycline. Among the 14 isolated MDR *E. cloacae*, 100% were resistant to amoxiclav, cefoxitin, ciprofloxacin, cefuroxime, ceftriaxone, ceftazidime and amikacin, 71.43% were resistant to piperacillin-tazobactam, 85.71% were resistant to imipenem, 50% were resistant to fosfomycin, 42.85% were resistant to colistin and 28.57% were resistant to tigecycline. Among the 3 isolated MDR *E. aerogenes*, all were resistant to amoxiclav, amikacin and cefoxitin, 66.67% were resistant to cefuroxime, ceftriaxone, ceftazidime and piperacillin-tazobactam, 33.33% were resistant to imipenem, ciprofloxacin, colistin and fosfomycin and no isolated *E. aerogenes* were resistant to tigecycline.

Table 3: Antibiotic resistance pattern of isolated multidrug resistant (MDR) *E. cloacae* and *E. aerogenes* (N=17)

Antimicrobial drugs	<i>E. cloacae</i>	<i>E. aerogenes</i>	Total
	N=14 n (%)	N=3 n (%)	N=17 n (%)
Amoxiclav	14 (100.00)	3 (100.00)	17 (100.00)
Cefoxitin	14 (100.00)	3 (100.00)	17 (100.00)
Ciprofloxacin	14 (100.00)	1 (33.33)	15 (88.23)
Cefuroxime	14 (100.00)	2 (66.67)	16 (94.12)
Ceftriaxone	14 (100.00)	2 (66.67)	16 (94.12)

Ceftazidime	14 (100.00)	2 (66.67)	16 (94.12)
Aztreonam	11 (78.57)	1 (33.33)	12 (70.59)
Amikacin	14 (100.00)	3 (100.00)	17 (100.00)
Imipenem	12 (85.71)	1 (33.33)	13 (76.47)
Piperacillin-tazobactam	10 (71.43)	2 (66.67)	12 (70.59)
Fosfomycin	7 (50.00)	1(33.33)	8 (47.06)
Cefepime	5 (35.71)	1 (33.33)	6 (35.29)
Colistin	6(42.85)	1 (33.33)	7(41.18)
Tigecycline	4 (28.57)	0 (0.00)	4 (23.53)

Table-4 shows detection of *fosA*, *fosA3*, *fosA4*, *fosA5*, *fosB*, *fosB2*, *fosC*, *fosC2* and *fosX* genes among fosfomycin resistant *E. cloacae* and *E. aerogenes* by PCR. Among 10 fosfomycin resistant *Enterobacter* spp. 7 (70) were positive for *fosA*, 5 (50) were positive for *fosA4*, and 4 (40) were positive for *fosA5*. No *fosA3*, *fosB*, *fosC*, *fosC2* and *fosX* gene were detected. No *fosA*, *fosA3*, *fosA4*, *fosA5*, *fosB*, *fosB2*, *fosC*, *fosC2* and *fosX* were detected from blood sample. This table also shows detection of *mcr-1* and *mcr-2* genes from different isolates among colistin resistant *E. cloacae* and *E. aerogenes* by PCR. Among 7 colistin resistant isolates no *mcr-1* and *mcr-2* genes were detected. No *mcr-1* and *mcr-2* gene detected from blood sample. This table also shows detection of *blaNDM-1*, *blaKPC*, *blaIMP*, *blaVIM* and *blaOXA-48 / blaOXA181* among imipenem resistant *Enterobacter* species by PCR. Among 9 imipenem resistant isolates. No *blaNDM-1*, *blaKPC*, *blaIMP*, *blaVIM* and *blaOXA-48 / blaOXA181* genes were detected. No *mcr-1* and *mcr-2* gene detected from blood sample.

Table 4: Detection of *fosA*, *fosA3*, *fosA4*, *fosA5*, *fosB*, *fosB2*, *fosC*, *fosC2* and *fosX* genes among fosfomycin resistant *E. cloacae* and *E. aerogenes* by PCR (N=10), *mcr-1* and *mcr-2* genes from different isolates among colistin resistant *E. cloacae* and *E. aerogenes* by PCR (N=8) & *blaNDM-1*, *blaKPC*, *blaIMP*, *blaVIM* and *blaOXA-48/ blaOXA181* among imipenem resistant *Enterobacter* species (N=9)

Genes	Urine	Wound swab	ETA	Total
	n (%)	n (%)	n (%)	n (%)
<i>fosA</i>	5(50.00)	2(10.00)	1(10.00)	8 (80.00)
<i>fosA3</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>fosA4</i>	2(20.00)	3(10.00)	0 (0.00)	5(50.00)
<i>fosA5</i>	4 (40.00)	1 (10.00)	0 (0.00)	4(50.00)
<i>fosB</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>fosB2</i>	0(0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>fosC</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>fosC2</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>fosX</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>mcr-1</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
<i>mcr-2</i>	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)

blaNDM-1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
blaKPC	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
blaIMP	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
blaVIM	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
blaOXA-48	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
/181				

N=Total number of fosfomycin resistant or colistin resistant or imipenem resistant *E. cloacae* and *E. aerogenes*.

n= Total number of fosfomycin resistant or colistin resistant or imipenem resistant gene in different samples.

ETA= Endotracheal aspirates.

Figure-3 shows Comparison of DNA sequence of amplified PCR product of *fosA4* gene of *Enterobacter cloacae* which is 81% identical with *Escherichia coli* strain CRE1540 chromosome, complete genome available in gene bank (Accession number- gi|1320768276|CP019051.1) *fosA4* had point mutation at 169, 170, 171, 180, 192, 195, 197, 203, 214, 218, 219, 222, 228, 238, 244, 250 positions and addition at 128 and 214 position.

Figure 3: DNA sequence of amplified PCR product of *fosA4* using specific primer

```
AATGGAGATCTGTCTCCAGAGACCGAGTTTTATGAGAGCGCTGGCGCA
TA
GCGTATGACCGATGATTGATCACTGGTTAGTGTCTTTTGATAGAAAAA
G
ACGGGTGCCACTACGACCAGAGCTAACTGAAACCAGGGTGCCTGAGT
TG
GAGCCTCCTTAATTGCGGGCCGCTCCTCCCGCTTTCCTCCGCAAAAC
CG
GTCGTGCCAATGCTATAATCAATCACCAACGCGCTGGGAGTAGGCGT
TT
ACTT
```

Discussion

Multidrug resistance is the most important problem in antibiotic resistance in treating microorganisms and there is exponential increase in MDR over the last decade [11] The emergence of multidrug-resistant *Enterobacter* spp. isolates has a negative impact on the clinical outcome of infected patients and increasing mortality rates [12]. In the present study, out of 360 samples, 228 (66.11 %) samples were culture positive of which 29 (12.1 8%) were *Enterobacter* spp. These finding are in agreement with the recent studies in DMCH reported that 65.14% samples (urine, wound swab, ETA, blood) and 63.20% of samples (urine, wound swab, ETA, blood, sputum, pus) were culture positive [13, 14]. *Enterobacter* accounts for 11% of all nosocomially acquired blood, wound, respiratory tract and urinary tract infection [15]. These findings are nearly close to the present findings. In the present study, among 29 isolated *Enterobacter* spp. 24 (82.76 %) were identified as *Enterobacter cloacae* and

5 (17.24 %) were identified as *Enterobacter aerogenes* by biochemical tests. These findings were similar to the recent study in DMCH found that 22 (78.57%) were identified as *Enterobacter cloacae* and 6 (21.43%) were identified as *Enterobacter aerogenes* [13].

Moreover, a study in India reported that 77.94% were *E. cloacae* and 22.05% were *E. aerogenes* [16]. This similarity may be attributed to the fact that these two studies were conducted in same geographic areas. In the present study, 55.17% *Enterobacter* spp. were resistant to amikacin. Study in Iran reported 48.60% *Enterobacter* resistant to amikacin which was lower than the present findings [17]. The reason behind the higher resistance rate in the present study might be due to the fact that, there was a significant irrational use of antibiotic. In the present study, imipenem resistance in *Enterobacter* spp. was 44.83%. Imipenem resistance among the species varies widely in different parts of the world. Study in India reported that 53.8% imipenem resistance where as study in Palestine showed resistance rates as low as 12.2% [18, 19]. Studied from DMCH noted 28% and 42.86% imipenem resistance among *Enterobacter* spp [20, 13].

The frequency of imipenem resistant *Enterobacter* spp. is increasing in Bangladesh which is reflected by these studies. Among the isolated *Enterobacter* spp. 8 (27.59%) colistin resistant *Enterobacter* spp. were identified. A study in Korea reported that 16% of *Enterobacter* spp. were resistant to colistin [21]. Another study reported 13.9%- 20.1% colistin resistances in *Enterobacter* spp [22]. Now a day, the use of colistin has increased in *Enterobacter* which might be the reason for emergence of resistance of this reserve drug. In the present study, among the 29 isolated *Enterobacter* spp. 34.48 % were resistant to fosfomycin. A study in India reported that 40% *Enterobacter* spp. were resistant to fosfomycin which were in agreement with the present study [23]. All the resistant strains were isolated from urine sample which is close to the present study. In the present study, 60% of *Enterobacter* spp. resistant to fosfomycin were isolated from urine.

The reason behind such finding in present study might be due to horizontal transfer of resistance genes between different species. Plasmids containing ESBL and *fos* genes may facilitate the dissemination of antibiotic resistance. Recent studies indicate that the recombination of plasmid-encoding carbapenemase and fosfomycinase occurs via mobile elements, thus presenting new treatment challenges [24]. Clinical use of fosfomycin in Bangladesh is rare and there is no data regarding fosfomycin resistance. In the present study, among the fosfomycin resistant *Enterobacter* spp. 80% were positive for *fosA*, 50% were positive for *fosA4* and 40% were positive for *fosA5*. A study in China reported that 80% *Enterobacter* isolates were positive for *fosA* and 10% *E. cloacae* were positive for *fosA4* [25]. A recent study in DMCH reported resistance rate of *fosB2*

genes are 40% among fosfomycin resistant *Enterobacter* spp [13]. Acquisition of fosfomycin resistance by antibiotics modifying enzyme that shows a higher incidence in multidrug resistant strains. The multidrug resistance plasmid, pKP46 carries nine gene (*fosA* among them) conferred resistance to several antibiotics including penicillins, cephalosporins, fosfomycin, aminoglycosides, quinolones [26]. This multi resistance plasmid might be the reason behind increasing fosfomycin resistance among MDR *Enterobacter* spp.

The identification of *fosA4* gene in *Enterobacter cloacae* was also further validated by sequencing. In the present study, DNA sequence of amplified PCR product of *fosA4* gene detected in *E. cloacae* which was 81% identical with *Escherichia coli* which is available in gene bank (Accession no-gi|1320768276|CP019051.1) suggested that the *fosA4* gene found in *E. cloacae* in the present study might have been transferred from *Escherichia coli* through plasmid. In this study, DNA sequence of amplified PCR product and translated nucleotide base sequence of *fosA4* showed point mutations at multiple positions. Comparison of DNA sequence of amplified PCR product of *fosA4* gene of *Enterobacter cloacae* which is 81% identical with *Escherichia coli* strain CRE1540 chromosome, complete genome available in gene bank (Accession number- gi|1320768276|CP019051.1) *fosA4* had point mutation at 169, 170, 171, 180, 192, 195, 197, 203, 214, 218, 219, 222, 228, 238, 244, 250 positions and addition at 128 and 214 positions.

Conclusion

E. cloacae and *E. aerogenes* have been increasingly associated with multidrug resistance and one of the common threats for hospital patients of critical care unit. *E. cloacae* and *E. aerogenes* found to be resistant to most commonly used antibiotics, of which 58.62% were MDR. Among the fosfomycin resistant *Enterobacter* spp. 70% were positive for *fosA* gene, 50% were positive for *fosA4* & 40% were positive for *fosA5*. So antimicrobial susceptibility testing must be done before prescribing antibiotics due to the high rates of resistance of *Enterobacter* spp. to multiple antibiotics.

References

- Kim T, Hong SI, Park SY, Jung J, Chong YP, Kim SH, et al. Clinical features and outcomes of spontaneous bacterial peritonitis caused by streptococcus pneumoniae: A matched Case-control study. *Medicine* 95 (2016): e3796.
- Vishwanath S, Swetha PS, SuShMa M. Extended-Spectrum β -lactamase Production among *Enterobacter cloacae* and *Enterobacter aerogenes* at a Tertiary Care Center in Coastal Karnataka. *National Journal of Laboratory Medicine* 3 (2016).
- System NN. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. *American Journal of Infection Control* 31 (2003): 481-98.
- Chavda KD, Chen L, Fouts DE, Sutton G, Brinkac L, Jenkins SG, et al. Comprehensive genome analysis of carbapenemase-producing *Enterobacter* spp.: new insights into phylogeny, population structure, and resistance mechanisms. *MBio* 30 (2016): e02093-16.
- Preston KE, Radomski CC, Venezia RA. Nucleotide sequence of the chromosomal *ampC* gene of *Enterobacter aerogenes*. *Antimicrobial agents and chemotherapy* 44 (2000): 3158-62.
- Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing *Enterobacteriaceae*. *Clinical microbiology reviews* 31 (2018): e00079-17.
- Rui Y, Lu W, Li S, Cheng C, Sun J, Yang Q. Integrons and insertion sequence common region 1 (ISCR1) of carbapenem-non-susceptible Gram-negative bacilli in fecal specimens from 5000 patients in southern China. *International journal of antimicrobial agents* 52 (2018): 571-6.
- Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M. Phenotypic and genotypic characterization of *Enterobacteriaceae* with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. *Antimicrobial agents and chemotherapy* 54 (2010): 573-7.10.
- Cienfuegos-Gallet AV, Ocampo AM, Chavda K, Chen L, Kreiswirth BN, Jiménez JN. Molecular epidemiology of carbapenem-resistant *Enterobacter cloacae* complex infections uncovers high frequency of non-carbapenemase-producers in five tertiary care hospitals from Colombia. *bioRxiv*. 2018 Dec 12:494807.
- Ramos JR, Lletí MS. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. *Revista Española de Quimioterapia* 32 (2019): 45.
- Liu CP, Wang NY, Lee CM, Weng LC, Tseng HK, Liu CW, et al. Nosocomial and community-acquired *Enterobacter cloacae* bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre. *Journal of Hospital Infection* 58 (2004): 63-77.
- Munny NN, Shamsuzzaman SM, Hossain T. Antibiotic resistance and phenotypic and genotypic detection of colistin resistance among *Enterobacter* species isolated from patients of a tertiary care hospital, Bangladesh. *Archives of Microbiology & Immunology* 5 (2021): 337-52.

13. Sonia SJ, Uddin KH, Shamsuzzaman SM. Prevalence of Colistin Resistance in *Klebsiella pneumoniae* Isolated from a Tertiary Care Hospital in Bangladesh and Molecular Characterization of Colistin Resistance Genes among Them by Polymerase Chain Reaction and Sequencing. *Mymensingh Medical Journal: MMJ* 31 (2022): 733-40.
14. Patel KK, Patel S. *Enterobacter* spp:-An emerging nosocomial infection. *International Journal of Applied Research* 2 (2016): 532-8.
15. Bhat S, KLS, Rao AS, Rao GS. Antibacterial Susceptibility Pattern of Uropathogenic *Enterobacter* Species from a Tertiary Care Hospital. *Journal of Krishna Institute of Medical Sciences (JKIMSU)* 1 (2018): 7(4).
16. Mortazavi SH, Mansouri F, Azizi M, Alvandi A, KARBASFRUSHAN A, Madadi-Goli N, et al. Prevalence of class I and II integrons among MDR *Enterobacter cloacae* isolates obtained from clinical samples of children in Kermanshah, Iran. *Journal of Clinical & Diagnostic Research* 12 (2018).
17. Khajuria A, Praharaj AK, Kumar M, Grover N. Carbapenem resistance among *Enterobacter* species in a tertiary care hospital in central India. *Chemotherapy research and practice* (2014).
18. Adwan G, Rabaya D, Adwan K, Al-Sheboul S. Prevalence of β -lactamases in clinical isolates of *Enterobacter cloacae* in the West Bank-Palestine. *International Journal of Medical Research & Health Sciences* 5 (2016): 49-59.
19. FA, Tafneen. Detection of AMPC β -lactamases, extended spectrum β -lactamases and carbapenemases in common *Enterobacter* species by phenotypic and genotypic methods with their antibiotic resistance pattern (2018).
20. Hong YK, Lee JY, Ko KS. Colistin resistance in *Enterobacter* spp. isolates in Korea. *Journal of Microbiology* 56 (2018): 435-40.
21. Dalmolin TV, de Lima-Morales D, Barth AL. Plasmid-mediated colistin resistance: what do we know?. *Journal of Infectiology and Epidemiology* 21 (2018).
22. Gopichand P, Agarwal G, Natarajan M, Mandal J, Deepanjali S, Parameswaran S, Dorairajan LN. In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections. *Infection and drug resistance* 9 (2019): 2005-13.
23. Tseng SP, Yang TY, Lu PL. Update on fosfomycin-modified genes in *Enterobacteriaceae*. *J Microbiol Immunol Infect* 52 (2017): 9-21.
24. Zhang R, Huang L, Hu YY. Prevalence of fosfomycin resistance and plasmid-mediated fosfomycin-modifying enzymes among carbapenem-resistant *Enterobacteriaceae* in Zhejiang, China. *J Med Microbiol* 66 (2017): 1332-1334.
25. Jiang Y, Shen P, Zhou Z, Zhang J, Yu Y, Li L. Complete nucleotide sequence of pKP96, a 67 850 bp multiresistance plasmid encoding qnrA1, aac(6')-Ib-cr and blaCTX-M-24 from *Klebsiella pneumoniae*. *J Antimicrob Chemother* 62 (2018): 1252-1256.
26. Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, et al. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary *Escherichia coli* isolates. *Journal of medical microbiology* 62 (2013): 1707-13.
27. Mlynarcik P, Roderova M, Kolar M. Primer Evaluation for PCR and its Application for Detection of Carbapenemases in *Enterobacteriaceae*. *Jundishapur journal of microbiology* 9 (2016).
28. Begum N, Shamsuzzaman SM. Emergence of carbapenemase-producing urinary isolates at a tertiary care hospital in Dhaka, Bangladesh. *Tzu Chi Medical Journal* 28 (2016): 94-98.
29. Y, Gallah S, Hommeril B, Genel N, Decré D, Rottman M, Arlet G. Emergence of plasmid-mediated fosfomycin-resistance genes among *Escherichia coli* isolates, France. *Emerging infectious diseases* 23 (2017): 1564.
30. Haeili M, Javani A, Moradi J, Jafari Z, Feizabadi MM, Babaei E et al. MgrB alterations mediated colistin resistance in *Klebsiella pneumoniae* isolates from Iran. *Front Microbiol* 8 (2017): 2470.